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Abstract
Background: In Gondar University Teaching Hospital standardized tuberculosis prevention and
control programme, incorporating Directly Observed Treatment, Short Course (DOTS) started
in 2000. According to the proposal of World Health Organization (WHO), treatment outcome is
an important indicator of tuberculosis control programs. This study investigated the outcome of
tuberculosis treatment at Gondar University Teaching Hospital in Northwest Ethiopia.
Methods: We analyzed the records of 4000 tuberculosis patients registered at Gondar University
Teaching Hospital from September 2003 to May 2008. Treatment outcome and tuberculosis type
were categorized according to the national tuberculosis control program guideline. Multivariate
analysis using logistic regression model was used to analyse the association between treatment
outcome and potential predictor variables.
Results: From the total of 4000 patients, tuberculosis type was categorized as extrapulmonary in
1133 (28.3%), smear negative pulmonary tuberculosis in 2196 (54.9%) and smear positive
pulmonary tuberculosis in 671 (16.8%) cases. Of all patients, treatment outcome was classified as
successfully treated in 1181(29.5%), defaulted in 730 (18.3%), died in 403 (10.1%), treatment failed
in six (0.2%) and transferred out in 1680 (42.0%) patients. Males had the trend to be more likely to
experience death or default than females, and the elderly were more likely to die than younger.
The proportion of default rate was increased across the years from 97(9.2%) to 228(42.9%). Being
female, age group 15-24 years, smear positive pulmonary tuberculosis and being urban resident
were associated with higher treatment success rate.
Conclusion: The treatment success rate of tuberculosis patients was unsatisfactorily low (29.5%).
A high proportion of patients died (10.1%) or defaulted (18.3%), which is a serious public health
concern that needs to be addressed urgently.
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Background
Tuberculosis (TB) is the leading cause of death from a cur-
able infectious disease [1]. According to the 2007 report of
World Health Organization (WHO), one-third of the
world's population is estimated to be infected with tuber-
cle bacilli and hence at risk of developing active disease,
in 2005, the annual incidence of TB, expressed as the
number of new TB cases, was globally about 8.8 million
people (7.4 million of these were in Asia and sub-Saharan
Africa), and the annual number of deaths due to TB was
1.6 million, including 195,000 patients infected with HIV
[2].
Important challenges for TB control are human immuno-
deficiency virus (HIV) co-infection and drug resistance
[3,4]. HIV co-infection is the strongest known risk factor
for progression of latent TB infection to TB disease [5].
Although HIV co-infection has been shown not to affect
the failure rate of TB treatment, high mortality has been
reported among HIV-infected TB patients in sub-Saharan
Africa [6].
According to the 2008 report of WHO, Ethiopia ranks sev-
enth among the world's 22 countries with a high tubercu-
losis burden [7]. The Ethiopian Federal Ministry of Health
(FMOH) hospital statistics data has shown that tuberculo-
sis is the leading cause of morbidity, the third cause of
hospital admission (after deliveries and malaria), and the
second cause of death in Ethiopia, after malaria [8]. Based
on the 2007 WHO estimates, in Ethiopia, the incidence of
TB of all forms and smear positive TB stand at 341 and
152 per 100,000 population, respectively. The prevalence
and mortality of tuberculosis of all forms is estimated to
be 546 and 73 per 100,000 population respectively [2].
In Ethiopia a standardized TB prevention and control pro-
gramme, incorporating Directly Observed Treatment,
Short Course (DOTS), was started in 1992 as a pilot in
Arsi and Bale zone, Oromia Region. The DOTS strategy
has been subsequently scaled up in the country and
implemented at national level. DOTS as a strategy was
introduced to the tuberculosis control programme at
Gondar University Teaching Hospital in 2000. Currently
the DOTS geographic coverage reaches 90%, whereas the
health facility coverage is 75% [8]. Like other developing
countries, in Ethiopia, culture and drug susceptibility test-
ing for M. tuberculosis are not performed routinely; even
for patients suspected of harboring drug-resistant strains.
DOTS during at least the first 2 months of treatment, in
which patients take drugs directly under the observation
of health care providers, has been recommended by inter-
national tuberculosis authorities[9,10], and has been
shown to be effective in achieving a high successful treat-
ment rate, from 86% to 96.5% [11]. The utility of DOTS
has also been demonstrated in developed countries. Jas-
mer et al reported that DOTS was significantly associated
with a higher treatment success rate than self-adminis-
tered therapy (97.8% vs. 88.6%, p < 0.002) and a lower
tuberculosis-related mortality rate (0% vs. 5.5%, p  =
0.002) [12]. DOTS also leads to significant reductions in
the frequency of primary drug resistance, acquired drug
resistance and relapse [13].
Correct treatment of tuberculosis aims at curing the
patient, interrupting transmission of tuberculosis to other
persons and preventing bacilli from becoming drug resist-
ant. These aims are not achieved in many regions of the
world even when anti tuberculosis drugs are available
[14]. The main reasons are death of the patients during
treatment, default before the scheduled end of treatment
or resistance to the drugs prescribed. Patient non-adher-
ence to treatment is interpreted as a failure of the health
care system to cope with the natural tendency of humans
to quit treatment as soon as they feel subjectively better,
or better without treatment if adverse drug events super-
vene [12].
Treatment outcome results serve as a proxy of the quality
of TB treatment provided by a health care system. Recom-
mendations on how to evaluate treatment outcomes
using standardized categories have been issued by the
World Health Organization (WHO) in conjunction with
the European Region of the International Union Against
Tuberculosis and Lung Disease (IUATLD) [15]. These cat-
egories were defined to assess the risk of future relapse and
drug resistance. Ideally, treatment outcome in all patients
should be routinely monitored by the epidemiological
surveillance system. This would make it possible to recog-
nize and amend system failures before the incidence and
proportion of resistant isolates rise. However, treatment
outcome of tuberculosis patients has not been assessed yet
in northwest Ethiopia. Therefore, this study is aimed to
assess treatment outcomes of pulmonary tuberculosis and
extrapulmonary tuberculosis cases at Gondar University
Teaching Hospital, Northwest Ethiopia.
Methods
Study setting
Gondar University Teaching Hospital (GUTH) is a tertiary
health care hospital serving the population of Gondar
town and remote hilly areas of northwest Ethiopia. The
total population served by the hospital is about 5 million.
In the hospital a Directly Observed Therapy; Short-Course
(DOTS) clinic is operating under the National Tuberculo-
sis and Leprosy Control Program (NTLCP) of Ethiopia,
under which the diagnosis of pulmonary TB is followed
by examination of three sputum smears by Zihel -Nielsen
staining method for acid fast bacilli (AFB). Chest radio-
graphs and pathological investigations are also used toBMC Public Health 2009, 9:371 http://www.biomedcentral.com/1471-2458/9/371
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support the diagnosis. Patients diagnosed with tuberculo-
sis are referred to the DOTS clinic where they are regis-
tered and treated according to the national TLCP
guideline [8].
Study design and data collection
A retrospective analysis of the profile and treatment out-
come of all tuberculosis patients registered from Septem-
ber 1, 2003 to May 31, 2008 at DOTS Clinic was
conducted. The registration documents reviewed contain
basic information such as patient's age, sex, address,
tuberculosis type, and treatment outcome. Institutional
ethical clearance was obtained from the Research and
Publication Committee of Gondar University.
Definition
According to the standard definitions of the National
Tuberculosis and Leprosy Control Program guideline
(NLCP) adopted from WHO [8], the following clinical
case and treatment outcome definitions were used:
Pulmonary TB, smear-positive
A patient with at least two sputum specimens which were
positive for acid-fast bacilli (AFB) by microscopy, or a
patient with only one sputum specimen which was posi-
tive for AFB by microscopy, and chest radiographic abnor-
malities consistent with active pulmonary TB.
Pulmonary TB, smear-negative
A patient with symptoms suggestive of TB, with at least
two sputum specimens which were negative for AFB by
microscopy, and with chest radiographic abnormalities
consistent with active pulmonary TB (including intersti-
tial or miliary abnormal images), or a patient with two
sets of at least two sputum specimens taken at least two
weeks apart, and which were negative for AFB by micros-
copy, and radiographic abnormalities consistent with pul-
monary TB and lack of clinical response to one week of
broad spectrum antibiotic therapy.
Extrapulmonary TB (EPTB)
This included tuberculosis of organs other than the lungs,
such as lymph nodes, abdomen, genitourinary tract, skin,
joints and bones, meninges, etc. Diagnosis of EPTB was
based on fine needle aspiration cytology or biochemical
analyses of cerebrospinal/pleural/ascitic fluid or his-
topathological examination or strong clinical evidence
consistent with active extrapulmonary tuberculosis, fol-
lowed by a decision of a clinician to treat with a full course
of anti-tuberculosis chemotherapy. In all the cases of
EPTB, sputum examinations and chest radiographs were
used to investigate the involvement of lung parenchyma.
This hospital lacks the facilities for culture and drug sus-
ceptibility testing.
Treatment Outcome
The treatment outcome was divided into seven categories
according to NTLCP guideline. These categories were:
cured (finished treatment with negative bacteriology result
at the end of treatment), completed treatment (finished
treatment, but without bacteriology result at the end of
treatment),  failure  (remaining smear positive at five
months despite correct intake of medication), defaulted
treatment  (patients who interrupted their treatment for
two consecutive months or more after registration), died
(patients who died from any cause during the course of
treatment),  transferred out (patients whose treatment
results are unknown due to transfer to another health
facility) and successfully treated(A patient who was cured
or completed treatment).
Statistical analysis
Data were entered, cleared and analysed using the statisti-
cal package SPSS for windows, version 13. To ensure the
quality of data entered into the computer, two people
were independently cross-checked each entry. For categor-
ical data, we used proportions with 95% confidence inter-
vals, Odds ratio and Chi-square test to compare different
groups. Multivariate analysis using logistic regression
model was used to analyse the association between treat-
ment outcome and potential predictor variables. P values
of less than 0.05 were considered statistically significant.
Results
Demographic characteristics of patients
A total of 4000 tuberculosis patients were registered at
Gondar University Teaching Hospital between September
2003 and May 2008. Of these, 2140(53.5%) were males
and 1860 (46.5%) were females with the mean (SD) age
of 27.7(15.2) years. Fifty one point five percent (n = 2062)
of the patients were urban resident and 2196 (54.9%)
patients were smear negative pulmonary tuberculosis.
Table 1 shows the general characteristics of the patients.
The proportion of tuberculosis types across the years are
shown in Table 2, where the number of smear negative
pulmonary tuberculosis cases (53.9%-56.5%) remained
highest compared to smear positive pulmonary tubercu-
losis cases (15.8%-17.9%) and extrapulmonary tubercu-
losis cases(25.6% - 30.1%) over the years.
Treatment outcome
We analyzed treatment outcome of 4000 tuberculosis
patients who were registered at the hospital during the
study period. Of these, 1181(29.5%) had successfully
treated, 730 (18.3%) defaulted, 403 (10.1%) died,
6(0.2%) treatment failure and 1680 (42.0%) transferred
out. The death rate of tuberculosis patients was steadily
decreased over the study period from 146(13.9%) in (Sep-
tember 2003 - August 2004) to 93(13.5%) in (SeptemberBMC Public Health 2009, 9:371 http://www.biomedcentral.com/1471-2458/9/371
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2004 - August 2005), 116(10.5%) in (September 2005 -
August 2006), 21(3.4%) in (September 2006 - August
2007) and 27(5.1%) in (September 2007 - May 2008).
However, default rate was increased across the years from
97(9.2%) in (September 2003 - August 2004) to
81(11.7%) in (September 2004 - August 2005),
165(14.9%) in (September 2005 - August 2006),
159(25.6%) in (September 2006 - August 2007) and
228(42.9%) in (September 2007 - May 2008) (table 2).
Table 3 shows that as the age of tuberculosis patients
increased, death rate of patients was increased from
34(4.6%), to 64(7.1%), 138(12.1%), 98(14.6%),
47(15.8%), 12(15.8%) and 10(10.1%) in the age groups
of 0 - 14 years, 15 - 24 years, 25 - 34 years, 35 - 44 years,
45 - 54 years, 55 - 64 years and > 65 years respectively. In
addition, males had the trend to be more likely to experi-
ence death (OR = 1.12, 95% CI = 0.91 - 1.38) or default
(OR = 1.15, 95% CI = 0.98 - 1.35) than females as an out-
come.
As shown in table 4, female tuberculosis patients had sig-
nificantly higher treatment success rate (32.5% vs. 27.0%;
p = 0.01) than males. Patients from rural areas, had signif-
icantly lower treatment success rate compared to cases
from urban (16.2% vs. 42%; p < 0.001). Furthermore,
patients in the age group of 25 - 34 years had significantly
low treatment success rate compared to other age groups
(P = 0.002; CI = 0.26 - 0.74).
Smear negative pulmonary tuberculosis patients had sig-
nificantly low treatment success rate (P < 0.001; CI = 0.35
- 0.54) compared to smear positive and extrapulmonary
tuberculosis patients. On the other hand, the highest
treatment success rate was observed among smear positive
pulmonary tuberculosis patients 321(47.8%) compared
to smear negative pulmonary tuberculosis and extrapul-
monary tuberculosis patients 564(25.7%) and
296(26.1%) respectively. In addition, the highest treat-
ment success rate (35.3%; p < 0.001; CI = 0.24 - 0.46) was
observed from September 2005 to August 2006 compared
to treatment success rates across the years during the study
period (table 4).
Table 1: General characteristics of study subjects (n = 4000), 
Gondar University Teaching Hospital, 2003-2008.
Characteristics Frequency Percent
Sex
Male 2140 53.5
Female 1860 46.5
Address
Urban 2062 51.5
Rural 1938 48.5
Age group(years)
0-14 747 18.7
15-24 901 22.5
25-34 1142 28.6
35-44 672 16.8
45-54 297 7.4
55-64 142 3.5
≥ 65 99 2.5
Tuberculosis type
Smear positive pulmonary TB 671 16.8
Smear negative pulmonary TB 2196 54.9
Extrapulmonary TB 1133 28.3
TB = tuberculosis
Table 2: Trends of treatment outcome and tuberculosis type across the years for all cases of tuberculosis, Gondar University Teaching 
Hospital, 2003-2008.
Treatment outcome 
& tuberculosis type
Years Total
N (%)
Sept.2003 - 
Aug.2004
N (%)
Sept.2004 - 
Aug.2005
N (%)
Sept.2005 -
Aug.2006
N (%)
Sept.2006 - 
Aug.2007
N (%)
Sept.2007 - May 
2008
N (%)
Treatment outcomes
Treatment success 321(30.5) 200(28.9) 390(35.3) 213(34.3) 57(10.7) 1181(29.5)
Transferred out 488(46.4) 317(45.9) 431(39.0) 226(36.4) 218(41.0) 1680(42.0)
Default 97(9.2) 81(11.7) 165(14.9) 159(25.6) 228(42.9) 730(18.3)
Death 146(13.9) 93(13.5) 116(10.5) 21(3.4) 27(5.1) 403(10.1)
Failure 0(0.0) 0(0.0) 2(0.2) 2(0.3) 2(0.4) 6(0.2)
Tuberculosis types
Smear positive 
pulmonary TB
172(16.3) 109 (15.8) 189(17.1) 111(17.9) 90(16.9) 671(16.8)
Smear negative 
pulmonary TB
583(55.5) 374(54.1) 601(54.4) 351 (56.5) 287(53.9) 2196(54.9)
Extrapulmonary TB 297(28.2) 208(30.1) 314(28.4) 159(25.6) 155 (29.1) 1133(28.3)
TB = tuberculosis, Sept = September, Aug = August, N = numberBMC Public Health 2009, 9:371 http://www.biomedcentral.com/1471-2458/9/371
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Discussion
According to the WHO 2005 report on global tuberculosis
control [16], the treatment success rates under the DOTS
programs among 22 high-burden countries (HBCs) varied
from 60% in Uganda to 93% in China, with an average of
83%. Moreover, the study conducted by B Shargie et al., in
Southern Ethiopia has shown that the treatment success
rate of all tuberculosis cases was 49% [17]. Our study
found that the treatment outcome of tuberculosis patients
treated under DOTS program at Gondar University Teach-
ing Hospital was unsatisfactory. The treatment success rate
of all tuberculosis cases was 29.5%. The low treatment
success rate observed in this study might be due to high
transferred out rate (42%), default rate (18.3%) and death
rate (10.1%), but the high treatment default rate and
death rate deserve special attention.
This study also demonstrated that death rate of tuberculo-
sis patients was significantly decreased across the years
from13.9% in (September 2003 - August 2004) to 3.4%
in (September 2006 - August 2007) (p < 0.001). This
might be due to increasing efforts to encourage tuberculo-
sis patients for HIV screening and initiating anti retroviral
therapy for TB/HIV co - infected patients at this hospital.
Patient registration documents we reviewed lack informa-
tion about the HIV status of our study subjects. However,
a previous study conducted by Kassu et al showed that
high proportions (52.1%) of TB patients were co-infected
with HIV at Gondar University Hospital [18].
As shown in table 3, we analyzed the death rate across the
age groups of tuberculosis patients and as the age increase
the death rate of patients was steadily increased from
4.6% in the age group of 0 - 14 years to 15.8% in the age
group of 55 - 64 years. This is in agreement with the find-
ing of a study conducted by Lee et al [19]. High age has
been previously reported to be a risk factor for death,
partly due to increasing comorbidities as well as the gen-
eral physiological deterioration with age [20-22], because
of which close monitoring of treatment in older patients
is necessary.
The default rate in this study (18.3%) was higher than the
average 6.2% among the 22 HBCs [16] and 10% among
the rural households in northwest Ethiopia [23]. On top
of that default rate of tuberculosis patients was signifi-
cantly (p < 0.001) increased across the years from
97(9.2%) in (September 2003 - August 2004) to
228(42.9%) in (September 2007 - May 2008) (Table 2).
According to studies conducted in central India [24] and
in Malawi [25] patients who completed treatment had a
better understanding of the duration of TB treatment than
patients who interrupted treatment. In other settings,
counseling [26], better supervision [27,28], home visits
and motivation [29,30] and health education [31] have
been used successfully as interventions to reduce default
rate of tuberculosis patients. The complementary results
obtained from the quantitative and qualitative compo-
nents of the study conducted in northwest Ethiopia also
Table 3: Treatment outcome by sex, address, age group and tuberculosis type, Gondar University Teaching Hospital, 2003-2008.
Characteristics Treatment outcomes Total
Treatment success
N(%)
Transferred out
N (%)
Default
N (%)
Death
N (%)
Failure
N (%)
Sex
Male 577(27.0) 921(43.0) 411(19.2) 226(10.6) 5(0.2) 2140
Female 604(32.5) 759(40.8) 319(17.2) 177(9.5) 1(0.1) 1860
Address
Urban 867(42.0) 590(28.6) 379(18.4) 222(10.8) 4(0.2) 2062
Rural 314(16.2) 1090(56.2) 351(18.1) 181(9.3) 2(0.1) 1938
Age group(years)
0-14 168(22.5) 439(58.8) 106(14.2) 34(4.6) 0(0.0) 747
15-24 373(41.4) 310(34.4) 151(16.8) 64(7.1) 3(0.3) 901
25-34 334(29.2) 433(37.9) 236(20.7) 138(12.1) 1(0.1) 1142
35-44 176(26.2) 260(38.7) 136(20.2) 98(14.6) 2(0.3) 672
45-54 74(24.9) 132(44.4) 44(14.8) 47(15.8) 0(0.0) 297
55-64 34(24.9) 63(44.4) 33(14.8) 12(15.8) 0(0.0) 142
≥ 65 22(22.2) 43(43.4) 24(24.2) 10(10.1) 0(0.0) 99
Tuberculosis type
Smear positive pulmonary TB 321(47.8) 195(29.1) 105(15.6) 46(6.9) 4(0.6) 671
Smear negative pulmonary TB 564(25.7) 987(44.9) 404(18.4) 239(10.9) 2(0.1) 2196
Extrapulmonary TB 296(26.1) 498(44.0) 221(19.5) 118(10.4) 0(0.0) 1133
TB = tuberculosis, N = numberBMC Public Health 2009, 9:371 http://www.biomedcentral.com/1471-2458/9/371
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indicate that the TB club approach has a significant impact
in improving patients' compliance to anti-TB treatment
and in building positive attitudes and practice in the com-
munity regarding TB [32]. Thus, the finding of this study
indicating the necessity of strengthening defaulter tracing
and interventions to reduce default rate of tuberculosis
patients in the study area.
The treatment failure rate varied from 0.1% in Zimbabwe
to 9.1% in the Russian Federation, with an average of
1.5% in HBCs [16]. The treatment failure rate in this study
was 0.2%, which is lower than the average failure rate of
the HBCs. This might be due to lower prevalence of multi
drug resistant strains of M. tuberculosis at the study area.
In our study the number of smear negative pulmonary
tuberculosis cases (53.9% -56.5%) remained highest com-
pared to smear positive and extrapulmonary tuberculosis
cases over the years. Similarly, registration in DOTS
(directly observed therapy, short course) programme
areas in Addis Ababa, Ethiopia has shown a continuous
increase in the proportion of smear-negative pulmonary
TB from 36.3% in 1992 to 66.3% in 1999 (G. Fishay, TB
co-ordinator, National Tuberculosis and Leprosy Control
Programme, personal communication, 1999). The large
number of smear negative pulmonary tuberculosis cases
might be due to high proportion of TB - HIV co-infection
at the study area, as shown by a previous study [18]. HIV-
infected patients are twice as likely to have sputum smear-
negative, culture-positive pulmonary TB (PTB) [33-35].
This results from their compromised immune response
causing less cavity formation [36].
The main limitations of our study were selection bias and
lack of information about the HIV status of the study sub-
jects. Nevertheless, our study reveals that TB is still a major
public health problem in Gondar University Teaching
Hospital. The results of the present study also indicate a
need for a coordinated tuberculosis control program
which should include active case surveillance, effective
care and treatment and quality laboratory diagnosis serv-
ices. Therefore, physicians should be encouraged to assess
HIV risk factors in patients who present with TB and to
offer HIV testing to all TB patients, to document the HIV
status of TB patients at TB clinic and to monitor treatment
responses. Furthermore, efforts should be made to
improve the quality of the laboratory diagnosis services.
Conclusion
The treatment success rate of pulmonary and extrapulmo-
nary tuberculosis patients treated at Gondar University
Teaching Hospital in northwest Ethiopia was unsatisfacto-
rily low (29.5%). A high proportion of patients died
(10.1%) or defaulted (18.3%), which is a serious public
health concern that needs to be addressed urgently. To
improve treatment outcome of tuberculosis patients we
recommend enhanced supervision and monitoring,
improved counseling during the intensive and continua-
Table 4: Crude and Adjusted odds ratios for various factors that might affect treatment outcome among tuberculosis patients, Gondar 
University Teaching Hospital, 2003-2008.
Characteristics Treatment success Crude OR 95% CI P-Value Adjusted OR* 95% CI P-Value
Yes
N (%)
No
N (%)
Sex
Male 577(27.0) 1563(73.0) 1.00 --- --- 1.00 --- ---
Female 604(32.5) 1256(67.5) 1.303 1.137-1.493 <0.001 1.215 1.048-1.409 0.010
Address
Urban 867(42.0) 1195(58.0) 1.00 --- --- 1.00 --- ---
Rural 314(16.2) 1624(83.8) 0.266 0.230-0.309 <0.001 0.275 0.235-0.322 <0.001
Age group(yrs)
0-14 168(22.5) 579(77.5) 1.00 --- --- 1.00 --- ---
15-24 373(41.4) 528(58.6) 0.985 0.595-1.630 0.952 0.697 0.409-1.188 0.184
25-34 334(29.2) 808(70.8) 0.404 0.247-0.662 <0.001 0.437 0.259-0.736 0.002
35-44 176(26.2) 496(73.8) 0.691 0.423-1.129 0.140 0.770 0.458-1.293 0.323
45-54 74(24.9) 223(75.1) 0.805 0.486-1.333 0.400 0.832 0.489-1.418 0.499
55-64 34(23.9) 108(76.1) 0.861 0.501-1.480 0.588 0.941 0.531-1.667 0.834
≥ 65 22(22.2) 77(77.8) 0.908 0.493-1.672 0.756 0.934 0.490-1.780 0.835
TB type
Smear positive pulmonary TB 321(47.8) 350(52.2) 1.00 --- --- 1.00 --- ---
Smear negative pulmonary TB 564(25.7) 1632(74.3) 0.386 0.315-0.472 <0.001 0.430 0.345-0.535 <0.001
Extrapulmonary TB 296(26.1) 837(73.9) 1.023 0.869-1.205 0.782 1.019 0.856-1.213 0.831
TB = tuberculosis, OR = Odds Ratio, CI = Confidence interval, N = number, yrs = years
* = All the variables in the table are included in the model.BMC Public Health 2009, 9:371 http://www.biomedcentral.com/1471-2458/9/371
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tion phases of treatment, home visits and motivation of
patients (defaulter tracing) and health education to
reduce treatment interruption.
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